MYO NYSE Orthopedic, Prosthetic & Surgical Appliances & Supplies Financials FY2016βFY2025
Myomo, Inc. had $40.9M of revenue in fiscal 2025, up 25.7% on the year before. Over five years, revenue changed +40.1% a year on average.
Last close Β· Oct 23, 2026
$1.21
0.8%Hi! I read Myomo, Inc.βs latest annual report (fiscal 2025). Here is what stands out:
Good So-so Weak
Are sales growing?
+25.7%
Yes. Sales grew 25.7% last year.
Does it make a profit?
β38.1%
No. It lost money last year.
Does profit turn into cash?
β39.7%
No. It spent more cash than it brought in.
How healthy are the accounts?
3 / 9
Weak. It passes 3 of 9 health tests.
How is the share priced?
β
No P/E: it made no profit over the last four quarters.
Rules of thumb on reported numbers. A starting point, not a recommendation.
Is it selling more, and how much does it keep?
KIRA Β· Myomo, Inc. had $40.9M of revenue in fiscal 2025, up 25.7% on the year before. Over five years, revenue changed +40.1% a year on average. Its operating margin was β35.2%, down 16.1Β pts: of every 100 in sales, about β35 is left after running the business.
In plain words: Revenue is all the money customers paid. The margins show how many cents of each dollar of sales are left over at each step: after making the product (gross), after running the business (operating) and after everything, tax included (net).
Revenue
Revenue
Margins, % of revenue
Margins, % of revenue
KIRA Β· Myomo, Inc. lost $15.6M in fiscal 2025.
Loss periods are shown in red.
In plain words: Net income is the profit left after every cost and tax. Earnings per share (EPS) splits that profit across every share, so it shows what one share earned.
Net income
Net income
Diluted EPS
Diluted EPS
How much cash comes in, and where does it go?
KIRA Β· Free cash flow was β$16.3M in fiscal 2025, β39.7% of revenue.
Cash from operations minus capital spending.
In plain words: Profit on paper is not the same as cash in the bank. Free cash flow is the cash left after paying to run and maintain the business: the money it can hand back to shareholders, save or invest.
Free cash flow
Free cash flow
Cash from operations vs capital spending
Cash from operations vs capital spending
In plain words: Companies hand cash back in two ways: dividends (cash paid to shareholders) and buybacks (buying back their own shares, so each remaining share owns a bigger slice).
Dividends and buybacks
Diluted shares outstanding (annual)
KIRA Β· In the last 12 months, insiders bought $0.4M and sold $0.1M of shares on the open market.
Open-market purchases and sales by officers, directors and 10% owners, from Form 4 filings. βPlanβ marks trades under a pre-arranged Rule 10b5-1 plan.
In plain words: Insiders are the people who run or own a big part of the company. Buying with their own money can signal confidence; selling often has personal reasons, like taxes or diversifying.
Bought, 12 months
$0.4M
4 insiders
Sold, 12 months
$0.1M
2 insiders
Of sales under plans
0%
$0.0M
| Date | Insider | Trade | Shares | Price | Value | Filing |
|---|---|---|---|---|---|---|
| Sep 11, 2026 | Harry KovelmanChief Medical Officer | Sold | 15,488 | $1.27 | $0.0M | Form 4 |
| Sep 2, 2026 | Milton Mayo MorrisDirector | Sold | 15,000 | $1.41 | $0.0M | Form 4 |
| Aug 20, 2026 | Harry KovelmanChief Medical Officer | Sold | 17,250 | $1.73 | $0.0M | Form 4 |
| Jun 5, 2026 | Thomas F KirkDirector | Bought | 40,002 | $1.27 | $0.1M | Form 4 |
| May 28, 2026 | Harry KovelmanChief Medical Officer | Sold | 11,536 | $1.02 | $0.0M | Form 4 |
| May 28, 2026 | Thomas F KirkDirector | Bought | 25,000 | $0.99 | $0.0M | Form 4 |
| May 27, 2026 | Harry KovelmanChief Medical Officer | Sold | 20,464 | $1.00 | $0.0M | Form 4 |
| May 18, 2026 | Thomas F KirkDirector | Bought | 43,401 | $0.91 | $0.0M | Form 4 |
| May 15, 2026 | Joseph M. Manko Jr.Director | Bought | 30,367 | $0.89 | $0.0M | Form 4 |
| May 15, 2026 | Thomas F KirkDirector | Bought | 31,605 | $0.91 | $0.0M | Form 4 |
| May 14, 2026 | Joseph M. Manko Jr.Director | Bought | 170,830 | $0.86 | $0.1M | Form 4 |
| Mar 16, 2026 | Heather C GetzDirector | Bought | 20,000 | $0.70 | $0.0M | Form 4 |
| Mar 13, 2026 | Thomas F KirkDirector | Bought | 72,000 | $0.71 | $0.1M | Form 4 |
| Mar 12, 2026 | Heather C GetzDirector | Bought | 70,000 | $0.73 | $0.1M | Form 4 |
| Nov 21, 2025 | Thomas F KirkDirector | Bought | 2,535 | $0.72 | $0.0M | Form 4 |
| Nov 20, 2025 | Thomas F KirkDirector | Bought | 4,902 | $0.72 | $0.0M | Form 4 |
| Nov 19, 2025 | Thomas Aloysius Crowley Jr.Director | Bought | 385 | $0.77 | $0.0M | Form 4 |
| Nov 18, 2025 | Thomas Aloysius Crowley Jr.Director | Bought | 4,000 | $0.73 | $0.0M | Form 4 |
| May 14, 2025 | Micah MitchellChief Commercial Officer | Sold | 90,231 | $0.86 | $0.1M | Form 4 |
Can it carry its debts, and how well does it use its money?
KIRA Β· Myomo, Inc. has $7.2M more cash than debt.
Cash, debt and the ratios that show how comfortably Myomo, Inc. can carry it.
In plain words: What the company owns and what it owes. More cash than debt is a cushion for bad times; a lot of debt leaves less room when business slows down.
Cash vs debt (incl. leases)
| Fiscal year end | FY21 | FY22 | FY23 | FY24 | FY25 |
|---|---|---|---|---|---|
| Cash and short-term investments | $15.5M | $5.3M | $8.9M | $24.9M | $18.4M |
| Debt incl. finance leases | β | β | β | $11.2M | $11.2M |
| Debt / equity | β | β | β | 0.5x | 1.0x |
| Current ratio | 4.5x | 2.6x | 2.5x | 3.2x | 3.3x |
| Quick ratio | 4.3x | 2.2x | 2.2x | 2.9x | 2.9x |
| Total assets | $20.1M | $10.2M | $14.6M | $42.2M | $38.6M |
| Total liabilities | $4.7M | $3.8M | $5.6M | $17.5M | $27.2M |
| Shareholders' equity | $15.4M | $6.4M | $9.0M | $24.7M | $11.4M |
| Net debt (β = net cash) | β | β | β | β$13.6M | β$7.2M |
KIRA Β· Its return on capital was β268.8%: every 100 invested in the business earned about β269 in a year.
After-tax operating income as a share of the money invested in the business: debt plus equity, minus cash.
In plain words: How much profit the business makes on the money put into it. A higher percentage means each dollar invested works harder.
Return on capital, equity and assets (annual)
KIRA Β· Myomo, Inc. passes 3 of 9 financial health tests (Piotroski F-score).
Nine pass/fail tests of profitability, funding and efficiency. 8β9 is strong, 0β2 weak.
In plain words: Nine yes/no tests of financial health, one point each. A green tick is a pass: 7 to 9 points is solid, 0 to 3 is weak.
| Test | FY16 | FY17 | FY18 | FY19 | FY20 | FY21 | FY22 | FY23 | FY24 | FY25 |
|---|---|---|---|---|---|---|---|---|---|---|
| Net income is positive | β | β | β | β | β | β | β | β | β | β |
| Cash from operations is positive | β | β | β | β | β | β | β | β | β | β |
| Return on assets rose | β | β | β | β | β | β | β | β | β | β |
| Cash from operations exceeds net income | β | β | β | β | β | β | β | β | β | β |
| Debt fell relative to assets | β | β | β | β | β | β | β | β | β | β |
| Current ratio rose | β | β | β | β | β | β | β | β | β | β |
| Share count didn't rise | β | β | β | β | β | β | β | β | β | β |
| Gross margin rose | β | β | β | β | β | β | β | β | β | β |
| Revenue rose relative to assets | β | β | β | β | β | β | β | β | β | β |
| F-score | β / 3 | 3 / 8 | 4 / 8 | 2 / 8 | 4 / 8 | 4 / 8 | 2 / 8 | 3 / 8 | 4 / 8 | 3 / 9 |
| Accruals ratio | β25.0% | β76.0% | β6.4% | β5.0% | β23.8% | β4.7% | β3.2% | β16.0% | β10.2% | β2.6% |
| Altman Z'' | β68.40 | 3.04 | β17.97 | β35.06 | β10.78 | β7.81 | β30.16 | β20.10 | β3.95 | β8.82 |
Every number, year by year.
Amounts in USD. Hover a ratioβs name for its definition.
In plain words: Every number we have, year by year. Download it as a spreadsheet if you want to dig deeper.
| Fiscal year | FY16 | FY17 | FY18 | FY19 | FY20 | FY21 | FY22 | FY23 | FY24 | FY25 |
|---|---|---|---|---|---|---|---|---|---|---|
| Income statement | ||||||||||
| Revenue | $1.1M | $1.6M | $2.4M | $3.8M | $7.6M | $13.9M | $15.6M | $19.2M | $32.6M | $40.9M |
| Gross profit | $0.8M | $1.1M | $1.7M | $2.4M | $5.0M | $10.3M | $10.3M | $13.2M | $23.2M | $26.9M |
| Research and development | $1.1M | $1.8M | $1.8M | $1.7M | $1.7M | $2.6M | $2.5M | $2.6M | $4.8M | $6.9M |
| Operating income | β$3.3M | β$6.5M | β$10.5M | β$10.8M | β$10.5M | β$10.3M | β$10.7M | β$8.2M | β$6.2M | β$14.4M |
| Interest expense | β | β | β | $0.1M | $0.2M | β | β | β | β | β |
| Pretax income | β | β | β | β | β$11.6M | β$10.3M | β$10.7M | β$8.0M | β$5.8M | β$15.1M |
| Income tax | $0.0M | $0.0M | β | β | β | $0.1M | $0.1M | $0.2M | $0.4M | $0.5M |
| Net income | β$3.6M | β$12.1M | β$10.3M | β$10.7M | β$11.6M | β$10.4M | β$10.7M | β$8.1M | β$6.2M | β$15.6M |
| Net income to common | β$4.4M | β$12.7M | β$10.3M | β$11.5M | β$12.2M | β$11.0M | β$10.7M | β | β | β |
| Diluted EPS | β$4.13 | β$2.93 | β$25.18 | β$20.79 | β$3.67 | β$1.89 | β$1.52 | β$0.28 | β$0.16 | β$0.37 |
| Diluted shares | 0.00B | 0.00B | 0.00B | 0.00B | 0.00B | 0.01B | 0.01B | 0.03B | 0.04B | 0.04B |
| Cash flow | ||||||||||
| Cash from operations | β$3.2M | β$6.2M | β$9.6M | β$10.3M | β$9.0M | β$9.5M | β$10.2M | β$6.2M | β$3.3M | β$14.5M |
| Capital expenditure | $0.0M | $0.1M | $0.1M | $0.1M | $0.0M | $0.3M | $0.1M | $0.1M | $1.4M | $1.7M |
| Free cash flow | β$3.2M | β$6.2M | β$9.7M | β$10.4M | β$9.1M | β$9.9M | β$10.3M | β$6.3M | β$4.7M | β$16.3M |
| Depreciation and amortization | $0.0M | $0.0M | $0.1M | $0.1M | $0.1M | $0.1M | $0.2M | $0.2M | $0.2M | $0.9M |
| Stock-based compensation | $0.1M | $0.3M | $0.8M | $0.9M | $0.6M | $1.1M | $1.2M | $1.1M | $0.9M | $2.1M |
| Balance sheet | ||||||||||
| Cash and short-term investments | $0.8M | $13.0M | $6.5M | $4.5M | $12.2M | $15.5M | $5.3M | $8.9M | $24.9M | $18.4M |
| Total debt | β | β | β | $2.7M | β | β | β | β | $11.2M | $11.2M |
| Current assets | $1.1M | $13.8M | $7.9M | $6.1M | $14.4M | $19.1M | $9.2M | $13.7M | $32.8M | $27.6M |
| Current liabilities | $3.0M | $1.5M | $1.9M | $3.9M | $2.9M | $4.3M | $3.6M | $5.5M | $10.2M | $8.3M |
| Inventory | $0.1M | $0.2M | $0.3M | $0.4M | $0.7M | $0.8M | $1.4M | $1.8M | $3.2M | $3.1M |
| Property and equipment, net | $0.0M | $0.1M | $0.2M | $0.2M | $0.1M | $0.3M | $0.2M | $0.2M | $1.3M | $2.2M |
| Total assets | $1.7M | $14.0M | $8.3M | $6.6M | $14.7M | $20.1M | $10.2M | $14.6M | $42.2M | $38.6M |
| Total liabilities | $6.5M | $1.5M | $1.9M | $4.8M | $3.1M | $4.7M | $3.8M | $5.6M | $17.5M | $27.2M |
| Preferred stock | β | β | β | β | β | $0.0M | $0.0M | $0.0M | $0.0M | $0.0M |
| Shareholders' equity | β$17.5M | $12.4M | $6.4M | $6.4M | $11.6M | $15.4M | $6.4M | $9.0M | $24.7M | $11.4M |
| Margins | ||||||||||
| Gross margin | 74.4% | 67.6% | 70.2% | 63.0% | 65.7% | 74.4% | 65.9% | 68.5% | 71.2% | 65.7% |
| Operating margin | β296.8% | β420.0% | β430.8% | β281.3% | β138.5% | β74.1% | β68.6% | β42.8% | β19.1% | β35.2% |
| EBITDA margin | β296.1% | β419.3% | β427.9% | β278.8% | β137.1% | β73.1% | β67.4% | β41.9% | β18.4% | β33.1% |
| Net margin | β327.8% | β776.0% | β422.1% | β279.2% | β152.5% | β74.9% | β68.9% | β42.3% | β19.0% | β38.1% |
| FCF margin | β290.5% | β399.0% | β398.2% | β270.8% | β119.7% | β71.3% | β66.5% | β32.8% | β14.3% | β39.7% |
| Returns | ||||||||||
| Return on capital | β | β | β | β184.9% | β | β | β | β | β44.3% | β268.8% |
| Return on capital employed | 243.9% | β52.4% | β163.8% | β397.6% | β88.7% | β64.9% | β162.7% | β90.4% | β19.4% | β47.5% |
| Return on equity | β | β | β109.3% | β166.7% | β128.5% | β76.9% | β98.5% | β106.2% | β36.7% | β86.2% |
| Return on assets | β218.1% | β154.8% | β92.7% | β144.0% | β108.5% | β59.6% | β70.9% | β65.9% | β21.8% | β38.5% |
| Return on tangible equity | β | β101.7% | β160.5% | β179.1% | β105.8% | β71.5% | β168.6% | β90.6% | β25.0% | β136.6% |
| Growth | ||||||||||
| Revenue growth | β | 41.3% | 56.8% | 57.0% | 97.6% | 82.7% | 12.3% | 23.7% | 69.2% | 25.7% |
| Share count change | β | 307.0% | β90.5% | 35.2% | 501.3% | 75.1% | 20.9% | 318.3% | 28.0% | 10.8% |
| Financial health | ||||||||||
| Debt / equity | β | β | β | 0.4x | β | β | β | β | 0.5x | 1.0x |
| Interest coverage | β | β | β | β95.0x | β48.0x | β | β | β | β | β |
| Current ratio | 0.4x | 9.3x | 4.2x | 1.6x | 5.0x | 4.5x | 2.6x | 2.5x | 3.2x | 3.3x |
| Quick ratio | 0.4x | 9.2x | 4.1x | 1.5x | 4.8x | 4.3x | 2.2x | 2.2x | 2.9x | 2.9x |
| Capital allocation | ||||||||||
| Capex / revenue | 0.2% | 4.3% | 5.2% | 1.4% | 0.6% | 2.4% | 0.7% | 0.8% | 4.2% | 4.3% |
| Stock comp / revenue | 8.5% | 17.9% | 33.3% | 23.7% | 8.1% | 7.9% | 7.7% | 5.8% | 2.7% | 5.1% |
| Quality scores | ||||||||||
| Piotroski F-score | β | 3.0 | 4.0 | 2.0 | 4.0 | 4.0 | 2.0 | 3.0 | 4.0 | 3.0 |
| Altman Z'' | β68.4 | 3.0 | β18.0 | β35.1 | β10.8 | β7.8 | β30.2 | β20.1 | β4.0 | β8.8 |
| Accruals ratio | β25.0% | β76.0% | β6.4% | β5.0% | β23.8% | β4.7% | β3.2% | β16.0% | β10.2% | β2.6% |
Source: SEC EDGAR XBRL filings (CIK 0001369290). Data updated October 24, 2026. Quarterly fourth quarters are the full year minus the first nine months. For information only β not investment advice. Check the original filings before relying on any figure.
